Description
LXS-196 is a selective inhibitor of protein kinase C (PKC). It is being investigated as a treatment for metastatic uveal melanoma, and may exhibit antitumor effects in other advanced tumors characterized by the overexpression of PKC.
Product Unit Size | Cost | Quantity | Stock |
---|
LXS-196 is a selective inhibitor of protein kinase C (PKC). It is being investigated as a treatment for metastatic uveal melanoma, and may exhibit antitumor effects in other advanced tumors characterized by the overexpression of PKC.
Cas No. | 1874276-76-2 |
---|---|
Purity | ≥98% |
Formula | C22H23F3N8O |
Formula Wt. | 472.48 |
Chemical Name | LXS-196 |
IUPAC Name | 3-Amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-2-pyrazinecarboxamide |
Synonym | LXS 196, LXS196, NVP-LXS196, Darovasertib |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Peptide, binds fibronectin.
Endogenous pterin coenzyme required for release...
Endogenous peptide hormone fragment, involved i...
Prodrug
NSAID; COX-1/2 inhibitor.
Mycotoxin produced by species of Aspergillus; D...
Peptide hormone found in eels; GnRH agonist, we...
Protein translation inhibitor.
Heterocyclic light-emitting compound, natural l...
SARS-CoV-2 inhibitor
Pleuromutilin
2’-Benzoylcarbonyl D-seco-Taxol is an impurit...
GHB/GABA analog found in Valeriana officinalis;...
EGFR inhibitor.
ACE inhibitor.
Sulfonamide; dihydropteroate synthase inhibitor...
Endogenous peptide, involved in vascular contra...
Low osmolarity contrast agent used for imaging ...
FLT3, c-Kit, PDGFR inhibitor.
Pan inhibitor of ALK.